Eikon Therapeutics IPO: offering terms from its S-1
Eikon Therapeutics priced its IPO at $18 a share on 5 Feb 2026 and raised $381 million. Its shares trade on Nasdaq as EIKN.
Headlines
- Net loss, 2024
- $244M
- IPO price
- $18
- $381M raised
Eikon Therapeutics IPO terms
From the final prospectus (424B4).
- Exchange
- Nasdaq Global Select Market
- Ticker
- EIKN
- IPO price
- $18
- Shares offered
- 21,177,600
- Raised
- $381M
- Registered
- $365M, the amount the filing fee is paid on
- Underwriters
- J.P. Morgan, Morgan Stanley, BofA Securities, Cantor and Mizuho
- First filed
- 9 Jan 2026
Eikon Therapeutics revenue and profit
| Period | Revenue | Operating income | Net income |
|---|---|---|---|
| 2024 | - | -$260M | -$244M |
| First nine months of 2025 | - | -$256M | -$245M |
Eikon Therapeutics share structure and company facts
- Employees
- 384
- Headquarters
- Millbrae, California
Eikon Therapeutics shares since the IPO
Latest close 26 Oct 2026
- IPO price
- $18
- Priced 5 Feb 2026
- First close
- $15.00
- -17% on the IPO price
- Latest close
- $5.54
- -69% on the IPO price
Eikon Therapeutics' IPO filings
The registration statement, each amendment and the final prospectus, oldest first.
About the data
- Terms and financials are read from Eikon Therapeutics' newest prospectus (424B4 filed 5 Feb 2026) by a Kadoa workflow. Check figures that matter against the filing.
- Registered is the amount the filing fee is paid on, often a placeholder before the price range is set.
- Raised is the IPO price times the shares sold, without the underwriters' option. Trading compares the first and latest close with the IPO price.